24/7 Market News Snapshot 09 December, 2024 – TNF Pharmaceuticals, Inc. Common Stock (NASDAQ:TNFA)

December 9, 2024

DENVER, Colo., 09 December, 2024 (247marketnews.com) – (Nasdaq:TNFA) are discussed in this article.
Today, TNF Pharmaceuticals, Inc. (Nasdaq:TNFA), a clinical stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory conditions, is witnessing a notable surge in its stock, currently trading at $1.547, reflecting a remarkable 24.76% increase since its last close at $1.240. The heightened trading volume of 657.54K signals robust investor interest and bullish sentiment, positioning TNFA as a stock to watch closely.

This momentum follows the company’s announcement of promising topline results from a Phase 2a study of its leading candidate, MYMD-1® (isomyosamine), aimed at treating sarcopenia. The findings were presented at a notable international congress dedicated to sarcopenia, where experts gathered to discuss advancements in the field. Dr. Mitchell Glass, President and Chief Medical Officer of TNFA, voiced optimism about MYMD-1’s potential to address the needs of patients lacking effective treatment options within the current therapeutic landscape.

The Phase 2a trial, which involved patients aged 65 and older experiencing chronic inflammation linked to sarcopenia, revealed significant decreases in crucial inflammatory biomarkers over a 28-day treatment period. Noteworthy declines in tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and soluble TNF-α receptor 1 (sTNFR1) were observed, with no serious adverse events reported.

Looking ahead, TNF Pharmaceuticals is set to launch a Phase 2b study targeting sarcopenia and frailty in early 2025, as they aim to address the significant healthcare gap in treating this condition, currently impacting an estimated 50 million people worldwide. With a glaring $3 billion market potential for sarcopenia treatments and increasing prevalence projected to exceed 200 million by 2060, TNF Pharmaceuticals is positioning itself as a leader in innovative solutions for age-related diseases, reaffirming its commitment to promoting healthier lifespans through groundbreaking research.

Related news for (TNFA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.